The American Heart Association 2022 Scientific Sessions included 35 late-breaking studies and 39 featured science sessions presented at the meeting in Chicago, Nov. 5-7. Here is the list of all these studies with links to more information on the data.

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

Researchers examined data from more than 1,800 CLTI patients, comparing bypass surgery with minimally invasive treatment options such as angioplasty and stenting.

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. 

Atrial fibrillation and peripheral artery disease, for example, are both predictors of mortality among women, but not men. 

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

Bhatt succeeds Valentin Fuster, MD, PhD, who has held the position since 2006 and will now serve in a more advisory role at Mount Sinai Heart.